American Journal of Transplantation · 2011 · 55 citations · 13 references
Life SciencesInfectious DiseasesNephrologyClinical ImmunologyKidney TransplantationTransplant ImmunologyGraft RejectionGraft-versus-host DiseaseImmunosuppressionImmunosuppression In Kidney TransplantationTransplant Infectious ComplicationsTransplant RejectionEpstein-barr Virus PersistenceImmune Monitoring After TransplantationInfection After TransplantationInfections After TransplantationInfectious Risk AssessmentPosttransplant Lymphoproliferative DisorderTransplant-associated Lymphoproliferative DisorderViral Infection Surveillance
Patients who undergo Epstein–Barr virus (EBV) seromismatch (D+/R−) transplants have a higher risk for the development of post-transplant lymphoproliferative disorder (PTLD). Adult renal transplant recipients at a single institution were prospectively monitored for EBV during the first year post-transplant. Over a 2-year period, 34 patients (7.78%) were identified as being EBV D+/R−recipients. Patients who developed symptoms or had persistent viremia were pre-emptively administered rituximab. Six recipients were discharged without monitoring on the protocol. Of those six, three (50%) developed PTLD and all three lost their grafts. Twenty (60.6%) of the 34 recipients developed viremia during the first year post-transplant. Of the recipients who became viremic, six (30%) received rituximab. None of the six who received rituximab-developed PTLD. We found that recipients who were not monitored on the protocol were more likely to have PTLD and graft loss compared to those who were (p = 0.008). Post-transplant monitoring of adults who undergo EBV D+/R−kidney transplants for viremia and symptoms associated with EBV infection may prompt intervention which reduces the incidence of PTLD within the first year. Use of rituximab in preventing PTLD among patients with primary EBV infection requires further prospective study to determine its overall safety and efficacy. Patients who undergo Epstein–Barr virus (EBV) seromismatch (D+/R−) transplants have a higher risk for the development of post-transplant lymphoproliferative disorder (PTLD). Adult renal transplant recipients at a single institution were prospectively monitored for EBV during the first year post-transplant. Over a 2-year period, 34 patients (7.78%) were identified as being EBV D+/R−recipients. Patients who developed symptoms or had persistent viremia were pre-emptively administered rituximab. Six recipients were discharged without monitoring on the protocol. Of those six, three (50%) developed PTLD and all three lost their grafts. Twenty (60.6%) of the 34 recipients developed viremia during the first year post-transplant. Of the recipients who became viremic, six (30%) received rituximab. None of the six who received rituximab-developed PTLD. We found that recipients who were not monitored on the protocol were more likely to have PTLD and graft loss compared to those who were (p = 0.008). Post-transplant monitoring of adults who undergo EBV D+/R−kidney transplants for viremia and symptoms associated with EBV infection may prompt intervention which reduces the incidence of PTLD within the first year. Use of rituximab in preventing PTLD among patients with primary EBV infection requires further prospective study to determine its overall safety and efficacy.
13
Joost W. J. van Esser, Hubert G.M. Niesters, Bronno van der Holt et al. · Blood · 2002 · 401 citations · Full text
Donald E. Tsai, Christine Hardy, John E. Tomaszewski et al. · Transplantation · 2001 · 364 citations
Medicine, Immunology, Surgery +16
Servi J.C. Stevens, Erik A.M. Verschuuren, Inge Pronk et al. · Blood · 2001 · 327 citations · Full text
Medicine, Hematology, Immunology +9